Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Rubin Lab
Explore this Website
Home
News
About Us
Research
Lab Team
Publications
Resources
Toggle Resources menu options
FISH
Profiler
Tracking Samples
Weill Cornell Medicine
Care
Discover
Teach
Home
News
About Us
Research
Lab Team
Publications
Resources
Home
Publications
Publications
Found 115 results
Author
Title
Type
Year
Filters:
Contact-us
is
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Akamatsu S
,
Wyatt AW
,
Lin D
,
Lysakowski S
,
Zhang F
,
Kim S
,
Tse C
,
Wang K
,
Mo F
,
Haegert A
et al.
. 2015.
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.
.
Cell Rep. 12(6):922-36.
Andrén O
,
Fall K
,
Franzén L
,
Andersson S-O
,
Johansson J-E
,
Rubin MA
. 2006.
How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden.
J Urol. 175(4):1337-40.
B
Baca SC
,
Prandi D
,
Lawrence MS
,
Mosquera JMiguel
,
Romanel A
,
Drier Y
,
Park K
,
Kitabayashi N
,
MacDonald TY
,
Ghandi M
et al.
. 2013.
Punctuated evolution of prostate cancer genomes.
.
Cell. 153(3):666-77.
Barbieri CE
,
Rubin MA
. 2015.
Genomic rearrangements in prostate cancer.
.
Curr Opin Urol. 25(1):71-6.
Barbieri CE
,
Chinnaiyan AM
,
Lerner SP
,
Swanton C
,
Rubin MA
. 2016.
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
.
Eur Urol.
Barbieri CE
,
Baca SC
,
Lawrence MS
,
Demichelis F
,
Blattner M
,
Theurillat J-P
,
White TA
,
Stojanov P
,
Van Allen E
,
Stransky N
et al.
. 2012.
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
.
Nat Genet. 44(6):685-9.
Barry M
,
Perner S
,
Demichelis F
,
Rubin MA
. 2007.
TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.
.
Urology. 70(4):630-3.
Beltran H
,
Rubin MA
. 2013.
New strategies in prostate cancer: translating genomics into the clinic.
.
Clin Cancer Res. 19(3):517-23.
Beltran H
,
Prandi D
,
Mosquera JMiguel
,
Benelli M
,
Puca L
,
Cyrta J
,
Marotz C
,
Giannopoulou E
,
Chakravarthi BVSK
,
Varambally S
et al.
. 2016.
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
.
Nat Med. 22(3):298-305.
Beltran H
,
Eng K
,
Mosquera JMiguel
,
Sigaras A
,
Romanel A
,
Rennert H
,
Kossai M
,
Pauli C
,
Faltas B
,
Fontugne J
et al.
. 2015.
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
.
JAMA Oncol. 1(4):466-74.
Beltran H
,
Danila D
,
B M
,
Szmulewitz R.
,
Vaishampayan U
,
Armstrong A.
,
Stein M.
,
Hoimes C
,
Pinski J.
,
Scher H.
et al.
. 2016.
A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)
.
Beltran H
,
Rickman DS
,
Park K
,
Chae SSuk
,
Sboner A
,
MacDonald TY
,
Wang Y
,
Sheikh KL
,
Terry S
,
Tagawa ST
et al.
. 2011.
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
.
Cancer Discov. 1(6):487-95.
Beltran H
,
Yelensky R
,
Frampton GM
,
Park K
,
Downing SR
,
MacDonald TY
,
Jarosz M
,
Lipson D
,
Tagawa ST
,
Nanus DM
et al.
. 2013.
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
.
Eur Urol. 63(5):920-6.
Berger MF
,
Lawrence MS
,
Demichelis F
,
Drier Y
,
Cibulskis K
,
Sivachenko AY
,
Sboner A
,
Esgueva R
,
Pflueger D
,
Sougnez C
et al.
. 2011.
The genomic complexity of primary human prostate cancer.
.
Nature. 470(7333):214-20.
Bismar TA
,
Demichelis F
,
Riva A
,
Kim R
,
Varambally S
,
He L
,
Kutok J
,
Aster JC
,
Tang J
,
Kuefer R
et al.
. 2006.
Defining aggressive prostate cancer using a 12-gene model.
.
Neoplasia. 8(1):59-68.
Blattner M
,
Liu D
,
Robinson BD
,
Huang D
,
Poliakov A
,
Gao D
,
Nataraj S
,
Deonarine LD
,
Augello MA
,
Sailer V
et al.
. 2017.
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
.
Cancer Cell. 31(3):436-451.
Boysen G
,
Barbieri CE
,
Prandi D
,
Blattner M
,
Chae S-S
,
Dahija A
,
Nataraj S
,
Huang D
,
Marotz C
,
Xu L
et al.
. 2015.
SPOP mutation leads to genomic instability in prostate cancer.
.
Elife. 4
Browne T-J
,
Hirsch MS
,
Brodsky G
,
Welch WR
,
Loda MF
,
Rubin MA
. 2004.
Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.
.
Hum Pathol. 35(12):1462-8.
C
Cancer Genome Atlas Research Network
. 2015.
The Molecular Taxonomy of Primary Prostate Cancer.
.
Cell. 163(4):1011-25.
Ceder Y
,
Bjartell A
,
Culig Z
,
Rubin MA
,
Tomlins S
,
Visakorpi T
. 2016.
The Molecular Evolution of Castration-resistant Prostate Cancer
.
European Urology Focus.
Chakravarty D
,
Sboner A
,
Nair SS
,
Giannopoulou E
,
Li R
,
Hennig S
,
Mosquera JMiguel
,
Pauwels J
,
Park K
,
Kossai M
et al.
. 2014.
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.
.
Nat Commun. 5:5383.
Cohen RJ
,
Wheeler TM
,
Bonkhoff H
,
Rubin MA
. 2007.
A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.
.
Arch Pathol Lab Med. 131(7):1103-9.
D
D'Alfonso TM
,
Subramaniyam S
,
Ginter PS
,
Mosquera JMiguel
,
MacDonald TY
,
Noorzad Z
,
Orta LY
,
Liu Y-F
,
Rubin MA
,
Shin SJ
. 2016.
Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast.
.
Hum Pathol.
Dardenne E
,
Beltran H
,
Benelli M
,
Gayvert K
,
Berger A
,
Puca L
,
Cyrta J
,
Sboner A
,
Noorzad Z
,
MacDonald T
et al.
. 2016.
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
.
Cancer Cell. 30(4):563-577.
Demichelis F
,
Greulich H
,
Macoska JA
,
Beroukhim R
,
Sellers WR
,
Garraway L
,
Rubin MA
. 2008.
SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.
.
Nucleic Acids Res. 36(7):2446-56.
1
(current)
2
3
4
5
next ›
last »